DAFNA Capital Management »

ImmunoGen shares owned by DAFNA Capital Management

Quarter-by-quarter ownership of ImmunoGen shares owned by DAFNA Capital Management from 13F filings

Historical chart of DAFNA Capital Management investment in ImmunoGen

Tip: Access up to 7 years of quarterly data

All positions including ImmunoGen held by DAFNA Capital Management consolidated in one spreadsheet with up to 7 years of data

Download as csvDownload consolidated filings csv Download as ExcelDownload consolidated filings xlsx

Quarterly reported holdings in ImmunoGen by DAFNA Capital Management

Quarter filed Position value Share count Share price at filing
2023-12-31 $5.7M 194k 29.65
2023-09-30 $1.3M 83k 15.87

More positions owned by DAFNA Capital Management

Spdr S&p Biotech Etf Etf (XBI)
Cytokinetics Com New (CYTK)
Stereotaxis Com New (STXS)
Ideaya Biosciences (IDYA)
Syndax Pharmaceuticals (SNDX)
Ascendis Pharma A/s Sponsored Adr (ASND)
Karuna Therapeutics Ord
Revolution Medicines (RVMD)
Ishares Nasdaq Biotech Indx Etf (IBB)
Xenon Pharmaceuticals (XENE)
Merus N V (MRUS)
Blueprint Medicines (BPMC)
Day One Biopharmaceuticals I (DAWN)
Neurocrine Biosciences (NBIX)
Dex (DXCM)

View all positions for DAFNA Capital Management

Top funds holding ImmunoGen

Vanguard Group
RA Capital Management
Redmile Group
Henderson Group
Pentwater Capital Management
Fairmount Funds Management
Norges Bank Investment Management
Millennium Management
D. E. Shaw & Co
Balyasny Asset Management
Voloridge Investment Management
Boxer Capital
Maverick Capital
TIG Advisors
Tang Capital Management

View all funds holding ImmunoGen